Serving patients with
commitment and humanity
We are currently evaluating the safety and tolerability of RLY-1971 in a Phase 1 dose escalation study in patients with advanced or metastatic solid tumors.
We are currently evaluating the safety and tolerability of RLY-4008 in a first-in-human dose escalation study in patients who have FGFR2 alterations in advanced solid tumors.
For questions or interest in participating in our clinical trials, please email us.
We are constantly working with patients, their families, caregivers, and advocacy groups to learn about the challenges patients experience in their daily lives and how we can best support them from a therapeutic perspective and beyond.